Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. - Wikidata - wikimedia - TriplyDB

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

http://www.wikidata.org/entity/Q34736974

about

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Critical appraisal of bevacizumab in the treatment of ovarian cancer Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Molecular genetics complexity impeding research progress in breast and ovarian cancers.The promise and challenge of ovarian cancer models.Leveraging global gene expression patterns to predict expression of unmeasured genes Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype Genetic and molecular changes in ovarian cancer.Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations.A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer.MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.Evaluation of functionalized mesoporous silica SBA-15 as a carrier system for Ph3Sn(CH2)3OH against the A2780 ovarian carcinoma cell line.Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.TP53 Mutations in Breast and Ovarian Cancer.The Unique Molecular and Cellular Microenvironment of Ovarian Cancer Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients.Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

P2860

Q26780387-A51A82C1-DD07-48FD-B909-704C24A6EFCE Q26830403-7B8207DC-9FFB-4FC1-95CE-5ADBCCDF0217 Q27307642-E0F37F18-7EEB-4999-AECD-40FD42359D91 Q28066904-1706138E-D9C3-4AEA-95E9-FA1F9FE88464 Q28071987-77AB75F5-6A30-432A-BC00-58A653FB106F Q28393224-2654FA9A-33D8-43BF-B386-6BA6D3909CEE Q33688593-A88FA57F-9E2E-43E2-AC82-FF42F25CBDA8 Q33858073-F888A1D0-EAA2-499D-9252-A5A3D2FF18D0 Q35771750-1AB817F2-F327-4E40-84D7-53AA81B370D7 Q35868350-A2AE6BCF-EB3B-4B7F-BAF6-6410BB73C1F8 Q36166608-B9A5072B-2B73-499E-9C73-B263C7E8615E Q36243394-8EE91B7E-1393-445F-B218-8E5B20C8BE6D Q36256775-E21EEE81-F36B-4A93-BD04-5901B1B91C89 Q36295033-AC5D552C-7C8D-4F0F-9446-FC9D47133CA1 Q36317366-9C25C6F8-5BE3-47F8-801C-23EC31FB5827 Q36372792-B1A11B42-EC95-4728-918D-8FC00D7A2CEE Q36544445-64264D00-7BA3-40C4-B2B8-845E7C89AC54 Q36685525-A6267648-1341-43D2-BB02-D9BECA288F84 Q37094076-5B87A11D-7F4D-4A32-B787-86EA9685E842 Q37096241-F3AE7436-5C19-45C1-B4B5-A70F47B48640 Q37147652-51CC7E7A-8BA2-4CC2-A6E6-F148DC6EB628 Q37157371-F969E944-B826-4A1A-A866-E3FDF1EDF270 Q37174032-CDF0C378-F979-40AF-AA4F-2A6C966ADAA5 Q37368631-38987623-031B-4695-9B06-00A660DF6CF7 Q37437254-798C0FD0-173D-4A36-8606-C3F4BD49F8C2 Q37485636-B3036962-D585-424F-8556-C1927AF94F17 Q37641608-F4215B35-EC55-4B89-92CC-5E459161D370 Q38714246-BB0F659B-472A-4D07-9FA2-E806D4CF1F29 Q38730893-0500D966-42E6-4F22-8A3F-184D198A7390 Q38747875-F9A06620-7CBB-40E6-9BE8-7F706910CE4E Q38787667-73C0398F-FDED-4695-ADB6-D146E7047D42 Q38903238-751150C3-668E-4FDC-897B-DD753259B0D8 Q38975570-F54D92CE-47E8-4002-B9FE-39851658E260 Q38999130-89D695C8-84A1-4E43-9CDC-8DBCB20A5C48 Q39169603-41ADE18D-D8B6-42A8-9931-9532984D9659 Q41557623-69AAAAF6-632B-4092-A57C-46957A99339B Q41685127-81FD85DC-E1E1-49C2-B51D-22223ACE86AC Q42229919-D3E73DAA-B6F9-46E5-9AEF-717CCD1B60EC Q42379619-758C013A-D261-40DC-B17A-505700DCFA7F Q43924266-20624F89-BE47-4D39-A411-AAA041523F17

P2860

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

http://www.wikidata.org/entity/Q34736974

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@ast

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@en

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@nl

type

label

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@ast

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@en

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@nl

prefLabel

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@ast

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@en

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@nl

P1433

Q34736974-FF25A76A-B187-4AF0-B10C-723DAB3D8D63

P1476

Q34736974-A8548528-C7E6-4478-BEA4-DB92EBAFD3D0

P2093

Q34736974-02502ADE-2F03-47C4-9523-1DC3DAEC05EC

Q34736974-13ABC4FE-46E4-403F-824F-69FF24D8958B

Q34736974-238B5C65-CAC6-4AFB-B520-4EE0B30FA40E

Q34736974-32AC9DA4-BCF0-4F2F-800C-18EABD63778A

Q34736974-3E37F6C1-7908-4C67-A48F-627514473BEB

Q34736974-3FED9799-F079-4A13-81DB-39E4F43BDE64

Q34736974-414A583D-C3AF-44BB-B2D6-9D0DF5D1DAF6

Q34736974-66220DE0-CDA5-4D06-B711-912DCF15722A

Q34736974-772B5777-8DC3-48C7-BA56-9E195024CE0C

Q34736974-848C9A45-7310-4079-B87C-29853ADAE973

P2860

Q34736974-1C9625AC-8061-446C-8555-49D1E527C2AF

Q34736974-5D42F808-E527-4F42-8A41-0E88413B6E60

Q34736974-64A128BE-A3C7-46CD-BCBB-ECAECD2222D9

Q34736974-6595EB4B-950E-442C-9992-4CD3B689B62B

Q34736974-6B5B9F4E-F0DB-4E41-A995-C661330CCDBF

Q34736974-8946A19C-0265-4402-A9C0-DBC3A53823B3

Q34736974-A9401B28-EF1A-4B50-95F0-B9A11D4DE310

Q34736974-B161F916-6DCB-4ACA-908F-5E188835771A

Q34736974-BEFF609E-DB1D-4CEA-AD83-59C4BCC8F3FE

Q34736974-C2A75077-734E-439C-922E-2B12A14FE403

P31

Q34736974-D47D4D72-FCF2-430F-ADC3-5D740700ECC2

P356

Q34736974-9464FA1A-E8C9-49DC-9311-9D6E6F6046B1

P407

Q34736974-0C4CC4A9-7E21-4F52-B885-7B9A484939DB

P433

Q34736974-37EF829C-7BF0-4F73-A739-96A51EB77798

P478

Q34736974-F6FFF544-3590-48BC-90E2-1138037B585C

P50

Q34736974-60528B4A-6C21-4452-BCF9-F2AF5F0766FF

Q34736974-A701E56F-C4F4-488D-BAA6-7F92BDCA2EAC

Q34736974-C2EEEFE7-2713-4AB4-80CA-ED622180E3CC

P577

Q34736974-E601ABBD-FA16-408A-BDDA-688327CBAAF4

P5875

Q34736974-A33F6632-12B0-49F2-91FD-C6235C5A2ACE

P698

Q34736974-9F8EC4B4-A75B-497B-87D0-88B2CD131FCB

P921

Q34736974-503633F9-6922-4CD1-B185-6DB11F34080D

P932

Q34736974-B79B0F9C-B3D3-4C5B-BB71-562BB3723633

P356

P1433

Journal of the National Cancer Institute

P1476

Prognostic and therapeutic rel ...... h-grade serous ovarian cancer.

@en

P2093

Bobbie Gostout

http://www.w3.org/2001/XMLSchema#string

Chen Wang

http://www.w3.org/2001/XMLSchema#string

Dennis J Slamon

http://www.w3.org/2001/XMLSchema#string

Ellen L Goode

http://www.w3.org/2001/XMLSchema#string

Gary Keeney

http://www.w3.org/2001/XMLSchema#string

Gottfried E Konecny

http://www.w3.org/2001/XMLSchema#string

Habib Hamidi

http://www.w3.org/2001/XMLSchema#string

He-Jing Wang

http://www.w3.org/2001/XMLSchema#string

Hsiao-Wang Chen

http://www.w3.org/2001/XMLSchema#string

Karl C Podratz

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Integrated genomic analyses of ovarian carcinoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Cancer statistics, 2013

A gene-expression signature as a predictor of survival in breast cancer

Tumor Immunotherapy Directed at PD-1

Direct multiplexed measurement of gene expression with color-coded probe pairs

Diagnosis of multiple cancer types by shrunken centroids of gene expression

Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

P31

scholarly article

P356

10.1093/JNCI/DJU249

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Charles Ginther

Boris Winterhoff

P577

2014-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266568407

http://www.w3.org/2001/XMLSchema#string

P698

25269487

http://www.w3.org/2001/XMLSchema#string

P921

P932

4271115

http://www.w3.org/2001/XMLSchema#string